Analysts' Actions: AGP, GPS, RIMM

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Amerigroup(AGP) rated new Buy at Jefferies. $100 price target. Company is leveraged to a robust Medicaid RFP pipeline.

Accretive Health (AH) downgraded from Outperform to Neutral at at Baird. $21 price target. Company just lost a major contract.

BJ's Restaurants(BJRI) rated new Overweight at Morgan Stanley. $59 price target. Company can deliver above-average growth over the next several quarters.

Gap(GPS) upgraded at Janney from Neutral to Buy. $33 price target. Better merchandising can drive inventory improvement.

Hecla Mining(HL) rated new Hold at Deutsche Bank. $5.50 price target. Lucky Mine remains closed.

Invensense(INVN) downgraded to Perform at Oppenheimer. Valuation call, based on a $15 price target.

Lufkin(LUFK) rated new Buy at Dahlman Rose. $96 price target. Company has solid pricing power, which could drive higher margins.

Lululemon Athletica(LULU) rated new Buy at UBS. $91 price target. Early innings of sales growth across channels and geographies.

Molina Healthcare(MOH) rated new Hold at Jefferies. Valuation call, as the stock is up 51% year-to-date. $37 price target.

Research in Motion(RIMM) downgraded at FBR Capital Markets from Market Perform to Underperform. $11 price target. Potential turnaround will likely take longer to develop.

United Natural(UNFI) rated new Sell at Cantor Fitzgerald. $33 price target. Earnings growth could lag sales.

US Bancorp(USB) downgraded at BMO Capital from Outperform to Market Perform. Valuation call, based on a $34 price target.

Vivus(VVUS) upgraded at Brean Murray to Buy, Brean. $30 price target. FDA appears to see more favorable results to weight loss.

Westport(WPRT) rated new Buy at Capstone. $49 price target. Demand should continue to grow for natural gas engines.

STOCK COMMENTS / EPS CHANGES

Apple(AAPL) estimates were raised by BMO Capital through 2013. iPad should continue to drive near-term growth, BMO said. Outperform rating and new $675 price target.

Best Buy(BBY) target lowered at UBS to $26. Stores lack a near term catalyst, UBS said. Neutral rating.